ASCO Reviewer Advises Genotyping to Improve Success for MEK-Inhibiting Cancer Drugs | GenomeWeb

Originally published June 6.

By Turna Ray

CHICAGO — In order to improve the chances that next-generation MEK inhibitors are commercialized for the treatment of melanoma and other solid tumors, researchers should take a more molecularly targeted approach by genotyping patients to stratify best responders to the drugs, a reviewer asserted at the American Society of Clinical Oncology's annual meeting here this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.